Cabio Biotech (Wuhan) Co., Ltd. (688089.SS)
CNY 24.7
(-1.24%)
CNY 24.7
(-1.24%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 152.91 Million CNY | 3.41% |
| 2022 | 113.91 Million CNY | -8.73% |
| 2021 | 178.01 Million CNY | -6.26% |
| 2020 | 135.77 Million CNY | 9.44% |
| 2019 | 169.88 Million CNY | 35.62% |
| 2018 | 117.29 Million CNY | 15.13% |
| 2017 | 104.25 Million CNY | 9.54% |
| 2016 | 82.34 Million CNY | 95.3% |
| 2015 | 48.09 Million CNY | -26.48% |
| 2014 | 74.66 Million CNY | -21.77% |
| 2013 | 81.44 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 16.34 Million CNY | -63.89% |
| 2024 Q2 | 45.25 Million CNY | 6.47% |
| 2024 Q1 | 27.43 Million CNY | -12.6% |
| 2023 Q3 | 30.15 Million CNY | -6.81% |
| 2023 Q4 | 40.36 Million CNY | 33.84% |
| 2023 Q2 | 32.36 Million CNY | 104.34% |
| 2023 Q1 | 15.83 Million CNY | -63.79% |
| 2023 FY | - CNY | 3.41% |
| 2022 Q4 | 43.73 Million CNY | 36.7% |
| 2022 FY | - CNY | -8.73% |
| 2022 Q3 | 31.99 Million CNY | -32.29% |
| 2022 Q2 | 47.25 Million CNY | 308.69% |
| 2022 Q1 | 11.56 Million CNY | -80.02% |
| 2021 Q3 | 30.15 Million CNY | -30.28% |
| 2021 Q2 | 43.24 Million CNY | 98.69% |
| 2021 Q4 | 57.88 Million CNY | 91.98% |
| 2021 Q1 | 21.76 Million CNY | -65.62% |
| 2021 FY | - CNY | -6.26% |
| 2020 Q3 | 36.36 Million CNY | -47.36% |
| 2020 Q1 | 19.7 Million CNY | -48.03% |
| 2020 Q2 | 69.07 Million CNY | 250.48% |
| 2020 FY | - CNY | 9.44% |
| 2020 Q4 | 63.31 Million CNY | 74.1% |
| 2019 Q4 | 37.92 Million CNY | -22.39% |
| 2019 FY | - CNY | 35.62% |
| 2019 Q3 | 48.85 Million CNY | 0.19% |
| 2019 Q2 | 48.76 Million CNY | 114.92% |
| 2019 Q1 | 22.68 Million CNY | -38.79% |
| 2018 FY | - CNY | 15.13% |
| 2018 Q4 | 37.06 Million CNY | 0.0% |
| 2017 FY | - CNY | 9.54% |
| 2016 FY | - CNY | 95.3% |
| 2015 FY | - CNY | -26.48% |
| 2014 FY | - CNY | -21.77% |
| 2013 FY | - CNY | 0.0% |